Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Posts higher annual loss in 2021. Pretax loss widens to £4.0 million from £14,000 in 2020. In May 2021, Cizzle was bought by Bould Opportunities PLC. Acquisition-related costs stand at £3.1 million in 2021 versus none in 2020.

Net assets grow to £1.2 million from £10,000 in 2020. The company does not make any revenue. Firm expects ‘to create a range of monoclonal antibodies and reagents’ regarding its lung-cancer focused collaboration with Portugal-based FairJourney Biologics. Cizzle aims to develop blood tests for the early detection of lung cancer, it explains.

Current stock price: 1.85 pence, up 2.8% on Monday

12-month change: down 74%

Copyright 2022 Alliance News Limited. All Rights Reserved.